| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Alirocumab |
| Brand | Praluent® |
| Indication | For the treatment of both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia |
| Assessment Process | |
| Rapid review commissioned | 13/10/2015 |
| Rapid review completed | 02/11/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 04/01/2016 |
| NCPE assessment completed | 06/06/2017 |
| NCPE assessment outcome | Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement. |
| The HSE has re-commissioned a full HTA for this product as of 20th March 2018 | |
| Full pharmacoeconomic assessment re-commissioned by HSE | 20/03/2018 |
| Pre-submission consultation with Applicant | 08/10/2018 |
| Submission received from Applicant | 27/02/2019 |
The HSE has approved reimbursement following confidential price negotiations, April 2021.